Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
April 24, 2025 01:00 ET | Source: Zealand Pharma Press release –…
Zealand Pharma launches long-term incentive programs for Zealand Pharmas Board of Directors, Corporate Management and employees for 2025
April 19, 2025 16:00 ET | Source: Zealand Pharma Company announcement –…
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025 16:01 ET | Source: BridgeBio Pharma, Inc. PALO ALTO,…
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc.…
Respilean Drops Exposed (MUST-READ): The Truth About Lung Support Big Pharma Doesnt Want You to Know
JUPITER, FLORIDA, April 02, 2025 (GLOBE NEWSWIRE) -- RESPILEAN In a world…
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
March 31, 2025 17:00 ET | Source: Zealand Pharma Company announcement –…
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
Company presented clinical and preclinical data at the MDA Conference last week…
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma
WOBURN, Mass., March 14, 2025 /PRNewswire/ -- Azurity Pharmaceuticals ("Azurity") announced today the successful…
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader…